MedPath

efficacy between Gunjaphaladi Lepa and Avalgujbeejadi Lepa in Vitiligo

Phase 2/3
Completed
Conditions
Vitiligo. Ayurveda Condition: Kilaasa ,
Registration Number
CTRI/2021/09/036825
Lead Sponsor
Government Ayuvedic College Patna
Brief Summary

In this study, 60 clinically diagnosed and confirmed patients of kilaasa (vitiligo) will be divided into 2 groups of 30 patients each.

Group I will be given Gunjaphaldi lepa and Group II will be given Avalgujbeejadi lepa.

The data will be collected and assessed by different scales of measurement. 6 evaluation will be done by follow up after every 15 days

The patients will be evaluated on the basis of subjective and objective parameter to assess the efficacy of the intervention.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
60
Inclusion Criteria
  • as per classical sign and symptoms described in ayurvedic texts and modern literature.
  • Prediagnosed patient of Kilaasa(vitiligo).
Exclusion Criteria
  • Patients below 12 yrs.
  • and above 60 yrs.
  • Chronicity of kilaasa more than 5 yrs.
  • Patients associated with diabetes, AIDS, Hep-B, leukemia -Pregnant women/lactating women -white anesthetic spots which are character of leprosy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The assessment will be based on the color, size,VETF, VIDA score, margins of the lesion and % of area involvement of the white patches.Patients will be followed up after 15 days up to 3 months of trial.
Secondary Outcome Measures
NameTimeMethod
Improvemeent in the quality of kilaasa(vitiligo)Evaluation will be done after 90 days.

Trial Locations

Locations (1)

Government Ayurvedic College & Hospital, Patna

🇮🇳

Patna, BIHAR, India

Government Ayurvedic College & Hospital, Patna
🇮🇳Patna, BIHAR, India
Dr Praveen Kumar
Principal investigator
9709834134
ayushpk5@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.